Skip to main content
Drug Development
Our Pipeline
Evaluation Pipeline
Therapeutic areas
Partnering
Useful Links
News
Investors
Regulatory News
AIM Rule 26
Annual and Half Yearly Reports
Admission Document & Articles
Shareholder communications
Investments Calculator
Share Alerts
Share Series
Share price look-up
Analyst Research
About us
Board of Directors and Management Team
Strategy and Vision
How we work
Working with us
Collaborative Pipeline
Contact us
Search
News
Breadcrumb
News
Category
Articles
Events and presentations
News
Press releases
Videos and audiocasts
News
ValiRx to host live Q&A shareholder webinar
7 Dec 2022
News
ValiRx attends Biotech Outsourcing Strategies 2022
21 Nov 2022
News
ValiRx CEO introduces Cytolytix at London South East webinar
9 Nov 2022
Videos and audiocasts
LSE Investor Presentation Introducing Cytolytix
9 Nov 2022
News
ValiRx attends Bio-Europe 2022
26 Oct 2022
News
ValiRx signs IP license agreement with Kings College London to progress triple negative breast cancer treatment
24 Oct 2022
News
ValiRx appoints NED to support growth and investment drive
19 Oct 2022
Articles
Ada Lovelace Day 2022: In conversation with ValiRx’s CEO
11 Oct 2022
Videos and audiocasts
ValiRx Q&A Live Webinar Held on 29th September 2022
29 Sep 2022
News
ValiRx bolsters drug discovery expertise with key appointment
23 Sep 2022
Videos and audiocasts
Successful evaluation of triple negative breast cancer programme
15 Jul 2022
Events and presentations
ValiRx - AGM & Live Q&A with Presentation Held on 30th June 2022.
1 Jul 2022
Videos and audiocasts
ValiRx - Live Q&A Webinar With Presentation Held on 6th April 2022
6 Apr 2022
Articles
ValiRx Recognised in the Biotechnology Awards 2022
5 Apr 2022
Pagination
Current page
1
Page
2
Page
3
Next page
Next
Last page
Last
